Results 41 to 50 of about 17,963 (297)
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
Frontiers in Endocrinology, 2022 BackgroundProlactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients.
Kejing Zhu +10 more
doaj +1 more source
A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology [PDF]
, 2016 Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and ...
Ansorge, Olaf +6 more
core +3 more sources
Cabergoline Treatment in Invasive Giant Prolactinoma
Clinical Medicine Insights: Case Reports, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Sadeem Alsubaie, Mussa H. Almalki
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2011 Management of prolactinoma in pregnancy is a big challenge for the treating obstetrician as prolactin levels are normally raised in pregnancy and this creates a possibility of missing the diagnosis of prolactinoma.
Sukhwinder Kaur Bajwa +3 more
doaj +1 more source
International Clinical Neuroscience Journal, 2020 Instruction: The current study reports a woman with pituitary adenoma and frontal convexity meningioma that was detected accidentally. To the best of our knowledge, this case is considered as a rare clinical scenario.
Thi Phuong Hoai Dinh +2 more
doaj +1 more source
Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro [PDF]
, 2001 Angiogenesis, the formation of a new blood supply, is an essential step in tumorigenesis. Although vascular endothelial growth factor (VEGF) is known to be a very potent angiogenic factor in most solid tumors, little is known about its production and ...
Gloddek, Jutta +7 more
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2021 Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma.
Rakesh Mishra +5 more
doaj +1 more source
Menstrual cycle abnormalities in patients with prolactinoma and drug-induced hyperprolactinemia
Indian Journal of Endocrinology and Metabolism, 2017 Background and Objective: Hyperprolactinemia affects the reproductive endocrine axis; however, the degree of dysfunction may vary depending on etiology.
Bindu Kulshreshtha +6 more
doaj +1 more source
A middle cerebral artery ischemic stroke occurring in a child with a large prolactinoma. [PDF]
, 2020 Pituitary adenomas are rare in children, and often present with symptoms of headache, nausea or emesis, visual disturbance, or hormonal hypersecretion.
Amara, Dominic +3 more
core
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. [PDF]
, 2013 OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly
AMATO, Marco Calogero +4 more
core +1 more source